Sanofi and Regeneron present positive new data on Praluent at ESC

29 August 2016

Much anticipated detailed positive results from ODYSSEY ESCAPE, a Phase III trial which evaluated Praluent (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment, have been released.

The positive results on Praluent, developed and marketed by French pharma major Sanofi (Euronext: SAN) and US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN), were presented today at a Hot Line session at the European Society of Cardiology (ESC) Congress 2016 in Rome, Italy.

Praluent is a human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, and is a novel and expensive class of drug vying for market space with similar agent Repatha (evolocumab) from Amgen (Nasdaq: AMGN), which also reported positive results at the ESC meeting (see separate article today).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK